Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: Mol Cancer Res. 2008 Aug;6(8):1375–1384. doi: 10.1158/1541-7786.MCR-07-2170

Figure 5. RNA gel shift assays comparing binding of wild type and mutated form of CSF-1 144nt 3′UTR to protein extract from Hey or NOSE.1 cells.

Figure 5

Mutations were created in 4 AU-rich regions within the terminal 144nt CSF-1 3′UTR as described in the text. Panels A&B represent results of binding of labeled wild type CSF-1 riboprobe to Hey (A) or NOSE.1 (B) protein extracts; Panels C&D represent results of binding of labeled mutant CSF-1 riboprobe to Hey (C) or NOSE.1 (D) protein extracts. Lanes 1, free riboprobe control; lanes 2, 1X probe mixed with 8 ug of protein extract; lanes 3, 3X probe mixed with 8ug of protein extract; lanes 4, 5 and 6, 1X probe mixed with 8 ug of protein extract in presence of 1500X, 770X or 390X excess cold probe, respectively.